CACCESE, MARIO
 Distribuzione geografica
Continente #
NA - Nord America 855
EU - Europa 114
AS - Asia 73
SA - Sud America 2
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 1.046
Nazione #
US - Stati Uniti d'America 855
CN - Cina 63
IT - Italia 55
FI - Finlandia 21
DE - Germania 12
GB - Regno Unito 8
SE - Svezia 8
IN - India 6
BE - Belgio 2
FR - Francia 2
IE - Irlanda 2
AT - Austria 1
EC - Ecuador 1
EU - Europa 1
GE - Georgia 1
HK - Hong Kong 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
PL - Polonia 1
PY - Paraguay 1
RS - Serbia 1
SG - Singapore 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 1.046
Città #
Fairfield 138
Chandler 133
Ashburn 84
Seattle 62
Woodbridge 55
Cambridge 49
Wilmington 48
Houston 43
Ann Arbor 42
Beijing 25
Padova 24
New York 20
Helsinki 19
Medford 16
Princeton 16
San Diego 14
Des Moines 11
Cagliari 6
Milan 5
Changsha 2
Chicago 2
Dublin 2
Kraainem 2
Lappeenranta 2
London 2
Los Angeles 2
Nanjing 2
Ogden 2
Redmond 2
Rome 2
Treviso 2
Verona 2
Washington 2
Asunción 1
Avezzano 1
Belgrade 1
Boardman 1
Bratislava 1
Canton 1
Deiva Marina 1
Delhi 1
Denver 1
Esslingen am Neckar 1
Falkenstein 1
Gubbio 1
Hamburg 1
Hebei 1
Hounslow 1
Islamabad 1
Jiaxing 1
Jinan 1
Kilburn 1
Majano 1
Nagold 1
Nanchang 1
Ottaviano 1
Pinehaven 1
Prescot 1
Pune 1
Quito 1
Shanghai 1
Shenyang 1
Tbilisi 1
Venice 1
Vienna 1
Wandsworth 1
Totale 871
Nome #
Letter to Editor: Reply to R.T. Casey (Semin Oncol. 2018 Jun;45(3):151-155) 155
Good tolerability of maintenance temozolomide in glioblastoma patients after severe hematological toxicity during concomitant radiotherapy and temozolomide treatment: report of two cases 97
Anaplastic Astrocytoma: State of the art and future directions 82
Comparison between18F-Dopa and 18F-Fet PET/CT in patients with suspicious recurrent high grade glioma: A literature review and our experience 76
Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab 75
Corneal side effects induced by EGFR-inhibitor antibody–drug conjugate ABT-414 in patients with recurrent glioblastoma: a prospective clinical and confocal microscopy study 66
Clinical management of diffuse low-grade gliomas 64
Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study 59
Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 study 52
PET/MR in recurrent glioblastoma patients treated with regorafenib: [18F]FET and DWI-ADC for response assessment and survival prediction 47
A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib 43
Ocular Side Effects of EGFR-Inhibitor ABT-414 in Recurrent Glioblastoma: A Long-Term Safety Study 41
Mismatch-repair protein expression in high-grade gliomas: A large retrospective multicenter study 39
PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review 31
Phosphorylated acetyl-coa carboxylase is associated with clinical benefit with regorafenib in relapsed glioblastoma: REGOMA trial biomarker analysis 25
Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter Study 23
Valutazione dell'attività di pembrolizumab in pazienti con recidiva di glioma di alto-grado e perdita parziale o completa di espressione delle proteine del mismatch repair: studio monocentrico, osservazionale, prospettico 20
Advanced Adrenocortical Carcinoma: From Symptoms Control to Palliative Care 16
Impressive response to dabrafenib and trametinib plus silybin in a heavily pretreated IDH wild-type glioblastoma patient with BRAFV600E-mutant and SOX2 amplification 14
The Overall Survival and Progression-Free Survival in Patients with Advanced Adrenocortical Cancer Is Increased after the Multidisciplinary Team Evaluation 13
Knowing when to discontinue Temozolomide therapy in responding aggressive pituitary tumors and carcinomas: a systematic review and Padua (Italy) case series 12
Metronomic Temozolomide in Heavily Pretreated Patients With Recurrent Isocitrate Dehydrogenase Wild-type Glioblastoma: A Large Real-Life Mono-Institutional Study 10
Prognostic role and interaction of TERT promoter status, telomere length and MGMT promoter methylation in newly diagnosed IDH wild-type glioblastoma patients 10
Case report: The lesson from opioid withdrawal symptoms mimicking paraganglioma recurrence during opioid deprescribing in cancer pain 4
Totale 1.074
Categoria #
all - tutte 6.248
article - articoli 6.151
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.399


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201919 0 0 0 0 0 0 0 0 0 0 10 9
2019/2020133 7 7 7 32 6 5 11 11 19 10 7 11
2020/2021229 5 34 4 14 31 10 23 27 32 9 31 9
2021/2022240 9 6 23 15 8 15 31 18 43 3 14 55
2022/2023235 36 33 8 29 27 26 1 20 31 7 15 2
2023/2024206 6 29 22 17 17 45 34 15 8 7 6 0
Totale 1.074